Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib plus abiraterone versus placebo plus abiraterone in post-docetaxel metastatic castration-resistant prostate cancer
NL-OMON53020Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in prostate cancer (PCa) and castration-resistant prostate cancer (CRPC) comparing Olaparib + abiraterone + prednisone/prednisolone with Placebo + abiraterone + prednisone/prednisolone (2 arms). Primary endpoint: Radiologic progression-free survival. Started Mar 2015; status: active, not recruiting.
02
Drugs
olaparibabiraterone
03
Conditions
prostate cancer (PCa)castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NL-OMON53020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53020.